Inspector AI vs Traditional Special Investigation Units (SIU)

Special Investigation Units have been the primary defense against fraud for decades. These teams of experienced investigators perform invaluable work: they investigate complex organized fraud cases, prepare files for legal action, and provide expert testimony before regulators and courts. For high-profile cases and sophisticated fraud schemes, human expertise is irreplaceable.

However, the traditional SIU model faces structural limitations when applied to pharmaceutical fraud. SIUs typically operate reactively — they investigate after payment has already been made. They work with samples because their human capacity cannot review every transaction. And their focus is calibrated for medical and hospital fraud, where individual amounts are large and patterns more obvious.

Pharmaceutical fraud is fundamentally different. It hides in millions of low-amount transactions that individually appear completely legitimate. A brand-name dispensation when a generic is available is technically correct. An early refill may have clinical justification. A same-molecule reauthorization passes all transactional validations. Only large-scale longitudinal pattern analysis reveals the systemic problem.

The result is that traditional SIUs detect only a fraction of actual pharmaceutical fraud. Our analysis of Latin American health insurance claims revealed that 43.4% of pharmaceutical spend shows detectable anomalies — a volume that no human team could process manually.

There are scenarios where the human expertise of an SIU is irreplaceable. Organized fraud investigations — networks of prescribers, pharmacies, and patients conspiring to defraud — require investigative techniques that go beyond data analysis. Interviews, surveillance, coordination with authorities, and building legal cases are exclusively human capabilities.

Regulatory and legal testimony requires investigators who can explain findings before courts and regulators. Managing relationships with law enforcement and regulatory bodies is the work of people, not algorithms. And contextual evaluation — understanding why an anomalous pattern may have a legitimate explanation in a specific case — requires human judgment.

Contextual intelligence is also an SIU domain. 80% of polypharmacy flags are correctly exempted by clinical logic — oncology, HIV, cardio-metabolic conditions, and neurology justify drug combinations that would be anomalous in other contexts. An experienced investigator understands these nuances.